Sun Pharmaceutical Industries Ltd on Tuesday reported a 10.51% increase in consolidated net profit at Rs 2,262.22 crore for the second quarter ended September 30, 2022.
The company posted a total net profit of Rs 2,047.01 crore for the same period last fiscal year, Sun Pharma said in regulatory filings.
Consolidated consolidated operating income was Rs. 10,952.28 crore compared to Rs. 9625.93 crore in the same quarter last fiscal year.
Total expenses in the pending quarter were higher at Rs. 8625.07 crore as compared to Rs. 7562.31 crore in the same period last year.
Dilip Shanghvi, managing director of Sun Pharmaceutical Industries, said that in the second quarter The company saw double-digit growth and strong profit margins driven by increasing market share in India. Global niche business growth and continued growth in emerging markets
”The global specialty business grew 27.5 percent, driven by (pharmaceuticals) Ilumya, Cequa and Winlevi. We remain focused on expanding our specialty business globally and expanding all of our businesses,” he added.
India’s formula sales were Rs 34.60 crore, up 8.5 per cent from the same period last fiscal year, Sun Pharma said U.S. sales of food ingredients were $412 million, up 14.1 percent, while Global exclusive sales surpassed $200 million, an increase of 27.5% compared to the second quarter of last year.
The company added that sales on the emerging market formula were $259 million. It was up 6.7 percent, while global sales were $181 million, down 3.8 percent from the same period last fiscal year. which is affected by unwanted currency movements .
(This story is not edited by Devdiscourse staff and is automatically generated from a curated feed.)